Through MTT and Transwell invasion assays, we confirmed the pro-cancer abilities of PLOD1 and PLOD2, which provided new basis for the molecular mechanism of RCC tumorigenesis. The gene discussed is PLOD2; the disease is renal cell carcinoma.